Skip to content
Company Analysis

Perspective Therapeutics, Inc. CATX

A comprehensive view of key metrics, scores, and financial health for Perspective Therapeutics, Inc.

Overview of Perspective Therapeutics, Inc.

CATX ASE
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Micro Cap
Perspective Therapeutics, Inc. (CATX), is a Micro Cap company, in the Medical Devices industry, last closed at $1.04, about 0.0% overvalued vs fair value, -53.4% 1Y return, ranked 742/1145 in sector.
Metrics ROE -41.4%
USD 1.04
-9.57%
(Delayed)
• Vol 90d: 102.9%
Market Cap
$118.72M
Enterprise Value
$71.83M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Weak
Completeness: 76%
Confidence: 86%
Updated: Oct 31
Top Beats
No strong beats yet

Quick Facts

Website https://www.perspectivetherape...
HQ Seattle, WA
Employees 138
Fiscal year Dec 31

Next Events

Earnings Nov 9 Estimated

Fair Value Snapshot

Insufficient data
Show more details
  • Revenue data missing or non-positive

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$0
Free Cash Flow
-$95.2M
-31%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

FCF Conversion
92%

Free Cash Flow / Net Income — not meaningful while net income is negative

Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
1/1
Improving
0
High Impact
1
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Perspective Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
25
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Conservative Leverage Leverage position is conservative vs peers (score 0.79). Balance sheet flexibility is a strategic asset for serial acquirers.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.13). May indicate commodity-like product mix or distributor margin drag.
  • Weak FCF Generation FCF margin quality lags peers (score 0.28). Below-peer FCF conversion is a MedTech quality warning.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
15
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing CATX's balance between Growth (20.0%), Profitability (28.3%), and Safety (51.7%). Growth 20% Safety 52% Profitability 28%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

16th percentile vs peers
16
Key Signals
EPS Growth YoY -13.5% 25p Rev Growth YoY -34.2% 11p Revenue CAGR 3Y -9.8% 14p Asset Growth YoY -21.7% 14p
Strengths
  • D/E Ratio in top 20% of peers (1.6%, 81th percentile)
  • Debt/Assets in top 20% of peers (1.2%, 92th percentile)
  • Equity/Assets in top 20% of peers (77.5%, 81th percentile)
  • Conservative leverage compared to industry peers
Risks
  • Growth in bottom 20% of peers (percentile: 16)
  • Rev Growth YoY in bottom 20% of peers (-34.2%)

Profitability

22th percentile vs peers
23
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

41th percentile vs peers
42
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Perspective Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000